Expert Opinion on Therapeutic Targets

Antiproteinuric therapy decreases LDL-cholesterol as well as HDL-cholesterol in non-diabetic proteinuric patients: relationships with cholesteryl ester transfer protein mass and adiponectin
pp. 497-504(8)
Authors: Krikken, JA; Waanders, F; Dallinga-Thie, GM; Dikkeschei, LD; Vogt, L; Navis, GJ; Dullaart, RPF

A critical role of COX-2 in the progression of neointimal formation after wire injury in mice
pp. 505-511(7)
Authors: Ogawa, Masahito; Suzuki, Jun-ichi; Hirata, Yasunobu; Nagai, Ryozo; Isobe, Mitsuaki

Resolvin E1 as a novel agent for the treatment of asthma
pp. 513-522(10)
Authors: Hisada, Takeshi; Ishizuka, Tamotsu; Aoki, Haruka; Mori, Masatomo

ADAM8: a new therapeutic target for asthma
pp. 523-540(18)
Authors: Knolle, Martin D; Owen, Caroline A

Nephroprotective and clinical potential of statins in dialyzed patients
pp. 541-550(10)
Authors: Rysz, Jacek; Aronow, Wilbert S; Stolarek, Robert S; Hannam, Simon; Mikhailidis, Dimitri P; Banach, Maciej

Therapeutic targets for Alzheimer's disease
pp. 551-567(17)
Authors: Tarditi, Alessia; Caricasole, Andrea; Terstappen, Georg

Inhibition of HGF/MET as therapy for malignancy
pp. 569-581(13)
Authors: Naran, Sanjay; Zhang, Xinglu; Hughes, Steven J

Novel factors as therapeutic targets to treat diabetes. Focus on leptin and ghrelin
pp. 583-591(9)
Authors: Gómez, Rodolfo; Lago, Francisca; Gómez-Reino, Juan J; Gualillo, Oreste

Molecular switching of osteoblastogenesis versus adipogenesis: implications for targeted therapies
pp. 593-603(11)
Authors: Takada, Ichiro; Kouzmenko, Alexander P; Kato, Shigeaki

Targeting the proteasome pathway
pp. 605-621(17)
Authors: Tsukamoto, Sachiko; Yokosawa, Hideyoshi

Erratum
pp. 623-623(1)